Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence.
about
Soy and breast cancer: focus on angiogenesis.Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine.Pazopanib: a Review in Advanced Renal Cell Carcinoma.The effect of medication nonadherence on progression-free survival among patients with renal cell carcinoma.Chamaejasmine B Induces the Anergy of Vascular Endothelial Cells to VEGFA Pro-angiogenic Signal by Autophagic Regulation of VEGFR2 in Breast Cancer.Systemic therapy in metastatic renal cell carcinoma
P2860
Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Optimal first-line and second- ...... l carcinoma: current evidence.
@ast
Optimal first-line and second- ...... l carcinoma: current evidence.
@en
Optimal first-line and second- ...... l carcinoma: current evidence.
@nl
type
label
Optimal first-line and second- ...... l carcinoma: current evidence.
@ast
Optimal first-line and second- ...... l carcinoma: current evidence.
@en
Optimal first-line and second- ...... l carcinoma: current evidence.
@nl
prefLabel
Optimal first-line and second- ...... l carcinoma: current evidence.
@ast
Optimal first-line and second- ...... l carcinoma: current evidence.
@en
Optimal first-line and second- ...... l carcinoma: current evidence.
@nl
P2093
P2860
P356
P1476
Optimal first-line and second- ...... l carcinoma: current evidence.
@en
P2093
Alessandro Larcher
Maxine Sun
Pierre I Karakiewicz
P2860
P304
P356
10.2147/IJNRD.S48496
P407
P577
2014-10-29T00:00:00Z